Research
Hormonal
GLP-1 receptor agonists (semaglutide, liraglutide) produce significantly greater weight loss than lifestyle modifications alone and are superior to older agents like orlistat and liraglutide (1.8mg).
If lifestyle changes alone haven't worked, GLP-1 agonists like semaglutide are highly effective. They work by mimicking a hormone that controls hunger. You take a weekly injection. Expect some stomach issues initially, but they often subside. These drugs are significantly more effective than older options like orlistat.
StrongSupportsVERY_HIGH confidence
Clinical trials showed that semaglutide leads to more weight loss compared with liraglutide... 86.4% versus 31.5% achieved weight reductions of 5% or more.
Why this rating
Supported by multiple double-blind RCTs (SCALE, STEP-1).
Source
Medical management of obesity
Sheena Gupta et al. · Clinical Medicine · 2023
DOI 10.7861/clinmed.2023-0183
narrative_reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery (specifically Roux-en-Y gastric bypass) provides the greatest long-term weight loss and diabetes remission rates compared to other surgical and non-surgical interventions.Strong
- A daily caloric deficit of at least 600 kcal, achieved through dietary intervention, is the foundational mechanism for sustainable weight loss and can induce type 2 diabetes remission.Good
- Optimizing medications by switching from weight-gain-causing drugs (antipsychotics, sulfonylureas, insulin) to weight-neutral or weight-loss agents (aripiprazole, SGLT2i, GLP-1 RA) facilitates weight management.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →